Pertuzumab

Generic Details

Generic Name

Pertuzumab

Other Names

  • Trade name: Perjeta

Drug Class

  • Monoclonal antibody

Chemical Formula

C6474H10046N1718O2038S42

Molecular Weight

148 kDa

Mechanism of Action

  • Inhibits the dimerization of HER2 receptor, leading to inhibition of signal transduction pathways

Indications

  • Breast cancer (HER2-positive)

Common Dosage Forms

  • Intravenous solution

Typical Dosage

  • Loading dose of 840 mg followed by 420 mg every 3 weeks

Pediatric Dosage

  • Safety and efficacy not established in children

Geriatric Dosage

  • Dose adjustment may be needed based on individual patient factors

Side Effects

  • Fatigue
  • Diarrhea
  • Nausea
  • Hair loss
  • Decreased appetite
  • Cardiotoxicity

Contraindications

  • Hypersensitivity to pertuzumab or any component of the formulation

Pregnancy Category

  • Category D - Positive evidence of risk

Lactation Safety

  • May be excreted in breast milk, risks vs. benefits should be considered

Drug Interactions

  • Trastuzumab
  • CYP3A4 inducers/inhibitors
  • Taxanes

Overdose Symptoms

  • Not well documented

Antidote for Overdose

  • No specific antidote, manage symptoms and provide supportive care

Storage Conditions

  • Refrigerate at 2°C to 8°C (36°F to 46°F), do not freeze

Pharmacokinetics

  • Absorption: Not applicable (IV administration)
  • Distribution: Volume of distribution: 3 to 5 L
  • Metabolism: Metabolized via proteolysis
  • Excretion: Mainly excreted in feces

Precautions

  • Monitor cardiac function before and during treatment
  • Regular monitoring of left ventricular ejection fraction (LVEF)

Warnings

  • Cardiomyopathy
  • Embryo-fetal toxicity
  • Infusion reactions

Others

  • Requires HER2 testing before use